Mesoblast Analyst Price Targets

Wall Street analyst price targets and consensus rating for Mesoblast (MESO).

Price Target Range — 4 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$26Upside to Avg. PT+96.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$35→$39
Nov 25, 2025	Jefferies	David Stanton	Upgrade	Hold→Buy	—
Jul 18, 2025	Jefferies	David Stanton	Downgrade	Buy→Hold	—
Feb 7, 2025	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$15→$24
Dec 23, 2024	Jefferies	David Stanton	Downgrade	Buy→Hold	—
Dec 19, 2024	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$11→$15
Sep 24, 2024	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$12
Aug 29, 2024	Jefferies	David Stanton	Upgrade	Hold→Buy	—
Aug 29, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
Jul 23, 2024	Piper Sandler	Edward Tenthoff	Upgrade	Neutral→Overweight	$4→$11
Jun 20, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
Jun 4, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.

Benzinga Newsdesk

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Avi Kapoor

PRO
Jefferies Upgrades Mesoblast to Buy

Jefferies analyst David Stanton upgrades Mesoblast (NASDAQ:MESO) from Hold to Buy.

Benzinga Newsdesk

This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Avi Kapoor

PRO
Jefferies Downgrades Mesoblast to Hold

Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:MESO) from Buy to Hold.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $24

Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $15 to $24.

Benzinga Newsdesk

Mesoblast Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Mesoblast Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

PRO
Jefferies Upgrades Mesoblast to Buy

This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

PRO
Jefferies Downgrades Mesoblast to Hold

PRO
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $24

People Also Watch

People Also Watch

Mesoblast Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Mesoblast Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

PROJefferies Upgrades Mesoblast to Buy

This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

PROJefferies Downgrades Mesoblast to Hold

PROPiper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $24

People Also Watch

People Also Watch

PRO
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

PRO
Jefferies Upgrades Mesoblast to Buy

PRO
Jefferies Downgrades Mesoblast to Hold

PRO
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $24